RMC-9805 is an oral, mutant-selective KRAS G12D(ON) inhibitor developed by Revolution Medicines, under clinical investigation for KRAS G12D-mutant solid tumors.
CAS: {2922732-54-3 }
Purity: ≥{98.4%}% (HPLC)
Stock: {562kg}
MOQ: {MOQ}（sample: 1 g）
Lead time: Samples: 3–5 days; Batch: 7–21 days
Documents: COA / HPLC / NMR / MSDS (available on request)
Physicochemical Properties
| M.Wt | 1168.44 | |
| Formula | C63H88F3N11O7 | |
| Appearance | Solid | |
| Storage |
|
|
| Solubility | 10 mM in DMSO | |
| Chemical Name/SMILES | (2S)-2-Cyclopentyl-2-((S)-7-((2R,3R)-3-cyclopropyl-1-methylaziridine-2-carbonyl)-2,7-diazaspiro[4.4]nonan-2-yl)-N-((22S,63S,4S)-12-(5-(4-cyclopropylpiperazin-1-yl)-2-((S)-1-methoxyethyl)pyridin-3-yl)-10,10-dimethyl-5,7-dioxo-11-(2,2,2-trifluoroethyl)-61,62,63,64,65,66-hexahydro-11H-8-oxa-2(4,2)-morpholina-1(5,3)-indola-6(1,3)-pyridazinacycloundecaphane-4-yl)acetamide | |
As a dedicated supplier of pharmaceutical intermediates and APIs, EOS Med CDMO offers RMC-9805 for research and development use, We support scale-up production up to kilogram levels and provide full Drug Master File (DMF) documentation support. Every shipment comes with complete technical dossiers, including COA, MSDS, and analytical data (HPLC/HNMR), to ensure seamless regulatory compliance for your project.
Specifications
CAS: 2922732-54-3
Synonyms: RMC9805
Target: KRAS G12D (ON inhibitor)
Research Area: KRAS G12D-mutant cancers
Transportation Conditions: This product is a non-hazardous chemical and should be transported at room temperature. It can be stably stored for several weeks during normal transportation and customs clearance.
Storage Conditions: Short-term (days to weeks) storage at 0-4°C; long-term (months to years) storage at -20°C.
Solubility: To be determined.
Shelf Life: Over 2 years under proper storage conditions.
Pharmaceutical Preparations: To be determined.
HS Code: 2934.99.9001